CheckMate 816 Trial: Neoadjuvant Nivolumab in Lung Cancer | ASCO 2025 Update

Описание: ARTICLE: https://oncologytube.com/neoadjuvant-...

OncologyTube.com presents an exclusive update from the CheckMate 816 trial, showcased at ASCO 2025 and published in the New England Journal of Medicine. This video explores the impact of neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer (NSCLC). Dr. Patrick Forde and a global team share key findings, including improved five-year survival rates, pathological complete response data, and safety profiles.

🔗 Read the full study in NEJM: https://www.nejm.org/doi/full/10.1056...

🔗 Visit OncologyTube.com for a written companion and more ASCO updates: OncologyTube.com

If you found this video helpful, please like, share, and subscribe for more oncology research updates!

Timestamps:

0:00 - OncologyTube.com Exclusive Video

0:02 - Introduction to CheckMate 816 Trial

0:13 - Study Overview by Dr. Patrick Forde

0:23 - Five-Year Survival Results

0:33 - Pathological Complete Response Data

0:42 - PD-L1 Subgroup Analysis

0:51 - Safety and Feasibility of Treatment

0:57 - Conclusion and Call to Action

1:08 - Subscribe and Visit OncologyTube.com

About OncologyTube.com:
OncologyTube.com is a free video-sharing platform dedicated to oncology professionals, offering cancer research updates through videos, audio, PowerPoint presentations, and more. Visit OncologyTube.com for a detailed web post on this ASCO 2025 coverage and other oncology insights.

Follow OncologyTube:
Twitter:   / oncologytube  
LinkedIn:   / oncologytube-com  
Facebook:   / oncologytube  
Instagram:   / oncologytube  
YouTube:    / oncologytube  

Connect with Us:
Share your thoughts in the comments! Use #ASCO25 to join the discussion. Subscribe for more oncology updates: https://oncologytube.com/newsletter/